Pronsati Nancee, Liu Geoffrey, Bauer Todd M, Felip Enriqueta, Goto Yasushi, Green Gerald, Grizzard Mary, Hamel Michael, Mazieres Julien, Mok Tony, Snow Stephanie, Solomon Benjamin J, Stratmann Jan, Culver Ken
Patient Author, Colorado, USA.
Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, ON M5G 2M9, Canada.
Lung Cancer. 2025 Aug;206:108662. doi: 10.1016/j.lungcan.2025.108662. Epub 2025 Jul 10.
Lorlatinib is an oral treatment for patients with advanced ALK-positive non-small cell lung cancer (NSCLC). Its efficacy was demonstrated in the CROWN clinical study, in which data from 5 years of follow-up demonstrated effective long-term disease control in patients with advanced ALK-positive NSCLC. While lorlatinib has a distinct side effect profile, its side effects are generally manageable. Managing side effects successfully is critical to preserving patient quality of life and promoting adherence to treatment-both of which are key to maximizing the long-term benefits of lorlatinib. The CROWN study showed that lorlatinib-associated side effects can be managed with dose adjustments, such as lowering the daily dose, without sacrificing treatment effectiveness. This guide, developed collaboratively by patients living with advanced ALK-positive NSCLC and healthcare professionals experienced with managing lorlatinib treatment, aims to help patients understand what to expect from treatment and how to take an informed, active role in their care.
洛拉替尼是一种用于治疗晚期ALK阳性非小细胞肺癌（NSCLC）患者的口服药物。其疗效在CROWN临床研究中得到了证实，该研究5年的随访数据表明，晚期ALK阳性NSCLC患者可实现有效的长期疾病控制。虽然洛拉替尼有独特的副作用，但这些副作用通常是可控的。成功管理副作用对于维持患者生活质量和促进治疗依从性至关重要，而这两者都是使洛拉替尼长期获益最大化的关键。CROWN研究表明，与洛拉替尼相关的副作用可通过调整剂量（如降低每日剂量）来管理，而不会影响治疗效果。本指南由晚期ALK阳性NSCLC患者与有洛拉替尼治疗管理经验的医疗专业人员共同制定，旨在帮助患者了解治疗预期以及如何在自身护理中做出明智、积极的选择。
